Curis Reports First Quarter 2015 Financial Results

Go back to Curis Reports First Quarter 2015 Financial Results

Curis (CRIS) Posts Q1 Loss of $0.30/Share

May 7, 2015 7:05 AM EDT

Curis (NASDAQ: CRIS) reported Q1 EPS of ($0.30), which may not compare with the analyst estimate of ($0.06). Revenue for the quarter came in at $1.17 million versus the consensus estimate of $2.27 million.

"The first quarter of 2015 was a potentially transformative period for Curis, highlighted by our entry into a broad, exclusive collaboration with Aurigene for the discovery, development and commercialization of small molecule drug candidates in the areas of immuno- and precision oncology," said Ali Fattaey, Ph.D., President and Chief Executive Officer of Curis. "This collaboration has the potential to generate a steady... More